This overview details Clario’s MRI-based imaging expertise for Multiple Sclerosis clinical trials. MRI is highlighted as a regulatory-recognized endpoint for assessing lesion burden, disease activity, and neurodegeneration. Clario offers advanced quantitative analyses including lesion detection, brain volumetry, atrophy measurement, DTI, MTI, and fMRI. Independent review by board-certified neuroradiologists supports eligibility, safety, and efficacy assessments. Centralized image review improves efficiency, reduces costs, and enables real-time data access. Comprehensive project management services ensure standardized protocols, site qualification, quality control, and full regulatory compliance across global MS trials.

Join for free to read